| GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH | 06/17 16:10 | globenewswire.com |
| GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis | 06/10 17:22 | globenewswire.com |
| US FDA approves Genfit and Ipsen's liver disease drug | 06/10 17:08 | reuters.com |
| GENFIT to Present Latest ACLF Research at EASL Congress™ 2024 | 05/29 16:10 | globenewswire.com |
| Genfit: Under The Radar Biotech With Upcoming Catalysts | 05/29 13:52 | seekingalpha.com |
| GENFIT: May 22, 2024 Combined Shareholders Meeting Results | 05/22 12:05 | globenewswire.com |
| GENFIT Reports First Quarter 2024 Financial Information | 05/14 16:10 | globenewswire.com |
| GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023) | 04/25 16:10 | globenewswire.com |
| GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents | 04/15 16:10 | globenewswire.com |
| GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F | 04/05 14:00 | globenewswire.com |